Opinion

Video

Overview of Non–Clear Cell RCC

Author(s):

Benjamin Garmezy, MD,Martin H. Voss, MD

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Minoo Battiwalla, MD, MS
David Rimm, MD, PhD
Related Content
Wenxin “Vincent” Xu, MD
October 25th 2024

Immunotherapy Combinations Dominate Frontline Discussions in Advanced RCC

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Aditya Bardia, MD, MPH, FASCO, of UCLA
October 15th 2024

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health
September 26th 2024

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

Eric Jonasch, MD, physician, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 14th 2024

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC

Mark G. Kris, MD, thoracic medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center
October 14th 2024

Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm